291 related articles for article (PubMed ID: 20659000)
1. Evaluating the utility of cardiomyocytes from human pluripotent stem cells for drug screening.
Dick E; Rajamohan D; Ronksley J; Denning C
Biochem Soc Trans; 2010 Aug; 38(4):1037-45. PubMed ID: 20659000
[TBL] [Abstract][Full Text] [Related]
2. Maturation of Pluripotent Stem Cell-Derived Cardiomyocytes: a Critical Step for Drug Development and Cell Therapy.
Tan SH; Ye L
J Cardiovasc Transl Res; 2018 Oct; 11(5):375-392. PubMed ID: 29557052
[TBL] [Abstract][Full Text] [Related]
3. Probing flecainide block of I
Geng L; Kong CW; Wong AOT; Shum AM; Chow MZY; Che H; Zhang C; Yau KL; Chan CW; Keung W; Li RA
Toxicol Lett; 2018 Sep; 294():61-72. PubMed ID: 29758359
[TBL] [Abstract][Full Text] [Related]
4. Cardiomyocytes derived from human pluripotent stem cells for drug screening.
Zeevi-Levin N; Itskovitz-Eldor J; Binah O
Pharmacol Ther; 2012 May; 134(2):180-8. PubMed ID: 22269465
[TBL] [Abstract][Full Text] [Related]
5. Developmental cues for the maturation of metabolic, electrophysiological and calcium handling properties of human pluripotent stem cell-derived cardiomyocytes.
Keung W; Boheler KR; Li RA
Stem Cell Res Ther; 2014 Jan; 5(1):17. PubMed ID: 24467782
[TBL] [Abstract][Full Text] [Related]
6. Cardiomyocytes from human pluripotent stem cells: From laboratory curiosity to industrial biomedical platform.
Denning C; Borgdorff V; Crutchley J; Firth KS; George V; Kalra S; Kondrashov A; Hoang MD; Mosqueira D; Patel A; Prodanov L; Rajamohan D; Skarnes WC; Smith JG; Young LE
Biochim Biophys Acta; 2016 Jul; 1863(7 Pt B):1728-48. PubMed ID: 26524115
[TBL] [Abstract][Full Text] [Related]
7. Cardiomyocytes derived from human embryonic stem cells - characteristics and utility for drug discovery.
Steel D; Hyllner J; Sartipy P
Curr Opin Drug Discov Devel; 2009 Jan; 12(1):133-40. PubMed ID: 19152222
[TBL] [Abstract][Full Text] [Related]
8. In vitro uses of human pluripotent stem cell-derived cardiomyocytes.
Matsa E; Denning C
J Cardiovasc Transl Res; 2012 Oct; 5(5):581-92. PubMed ID: 22639342
[TBL] [Abstract][Full Text] [Related]
9. Stem cells for drug screening.
Laposa RR
J Cardiovasc Pharmacol; 2011 Sep; 58(3):240-5. PubMed ID: 21499120
[TBL] [Abstract][Full Text] [Related]
10. Functional improvement and maturation of human cardiomyocytes derived from human pluripotent stem cells by barbaloin preconditioning.
Yang H; Zhong W; Hamidi MR; Zhou G; Liu C
Acta Biochim Biophys Sin (Shanghai); 2019 Sep; 51(10):1041-1048. PubMed ID: 31518384
[TBL] [Abstract][Full Text] [Related]
11. Use of Human Pluripotent Stem Cell Derived-Cardiomyocytes to Study Drug-Induced Cardiotoxicity.
Maillet A; Tan KP; Brunham LR
Curr Protoc Toxicol; 2017 Aug; 73():22.5.1-22.5.22. PubMed ID: 28777443
[TBL] [Abstract][Full Text] [Related]
12. Arrhythmogenicity Test Based on a Human-Induced Pluripotent Stem Cell (iPSC)-Derived Cardiomyocyte Layer.
Slotvitsky M; Tsvelaya V; Frolova S; Dementyeva E; Agladze K
Toxicol Sci; 2019 Mar; 168(1):70-77. PubMed ID: 30388253
[TBL] [Abstract][Full Text] [Related]
13. Engineering adolescence: maturation of human pluripotent stem cell-derived cardiomyocytes.
Yang X; Pabon L; Murry CE
Circ Res; 2014 Jan; 114(3):511-23. PubMed ID: 24481842
[TBL] [Abstract][Full Text] [Related]
14. Characterization of human-induced pluripotent stem cell-derived cardiomyocytes: bioenergetics and utilization in safety screening.
Rana P; Anson B; Engle S; Will Y
Toxicol Sci; 2012 Nov; 130(1):117-31. PubMed ID: 22843568
[TBL] [Abstract][Full Text] [Related]
15. Pluripotent Stem Cell-Based Platforms in Cardiac Disease Modeling and Drug Testing.
Shaheen N; Shiti A; Gepstein L
Clin Pharmacol Ther; 2017 Aug; 102(2):203-208. PubMed ID: 28718902
[TBL] [Abstract][Full Text] [Related]
16. Drug screening using a library of human induced pluripotent stem cell-derived cardiomyocytes reveals disease-specific patterns of cardiotoxicity.
Liang P; Lan F; Lee AS; Gong T; Sanchez-Freire V; Wang Y; Diecke S; Sallam K; Knowles JW; Wang PJ; Nguyen PK; Bers DM; Robbins RC; Wu JC
Circulation; 2013 Apr; 127(16):1677-91. PubMed ID: 23519760
[TBL] [Abstract][Full Text] [Related]
17. A Universal and Robust Integrated Platform for the Scalable Production of Human Cardiomyocytes From Pluripotent Stem Cells.
Fonoudi H; Ansari H; Abbasalizadeh S; Larijani MR; Kiani S; Hashemizadeh S; Zarchi AS; Bosman A; Blue GM; Pahlavan S; Perry M; Orr Y; Mayorchak Y; Vandenberg J; Talkhabi M; Winlaw DS; Harvey RP; Aghdami N; Baharvand H
Stem Cells Transl Med; 2015 Dec; 4(12):1482-94. PubMed ID: 26511653
[TBL] [Abstract][Full Text] [Related]
18. Rapamycin and CHIR99021 Coordinate Robust Cardiomyocyte Differentiation From Human Pluripotent Stem Cells Via Reducing p53-Dependent Apoptosis.
Qiu XX; Liu Y; Zhang YF; Guan YN; Jia QQ; Wang C; Liang H; Li YQ; Yang HT; Qin YW; Huang S; Zhao XX; Jing Q
J Am Heart Assoc; 2017 Oct; 6(10):. PubMed ID: 28971953
[TBL] [Abstract][Full Text] [Related]
19. Effective Hypothermic Storage of Human Pluripotent Stem Cell-Derived Cardiomyocytes Compatible With Global Distribution of Cells for Clinical Applications and Toxicology Testing.
Correia C; Koshkin A; Carido M; Espinha N; Šarić T; Lima PA; Serra M; Alves PM
Stem Cells Transl Med; 2016 May; 5(5):658-69. PubMed ID: 27025693
[TBL] [Abstract][Full Text] [Related]
20. Maturation of human pluripotent stem cell derived cardiomyocytes in vitro and in vivo.
Gomez-Garcia MJ; Quesnel E; Al-Attar R; Laskary AR; Laflamme MA
Semin Cell Dev Biol; 2021 Oct; 118():163-171. PubMed ID: 34053865
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
